ARK Genomic Revolution ETF (BATS:ARKG) Sets New 1-Year High – Still a Buy?

ARK Genomic Revolution ETF (BATS:ARKG) hit a new 52-week high during mid-day trading on Monday . The company traded as high as $37.71 and last traded at $37.31, with a volume of 407026 shares trading hands. The stock had previously closed at $36.86.

ARK Genomic Revolution ETF Stock Down 1.6%

The business’s 50 day moving average is $31.35 and its 200 day moving average is $30.07.

Institutional Investors Weigh In On ARK Genomic Revolution ETF

Institutional investors and hedge funds have recently modified their holdings of the company. SG Americas Securities LLC raised its holdings in shares of ARK Genomic Revolution ETF by 207.8% during the 4th quarter. SG Americas Securities LLC now owns 102,521 shares of the company’s stock valued at $2,970,000 after buying an additional 69,215 shares during the period. Canal Insurance CO bought a new stake in ARK Genomic Revolution ETF in the fourth quarter valued at about $3,476,000. Cresset Asset Management LLC lifted its stake in ARK Genomic Revolution ETF by 55.9% during the third quarter. Cresset Asset Management LLC now owns 121,062 shares of the company’s stock worth $3,362,000 after purchasing an additional 43,403 shares during the last quarter. Trivium Point Advisory LLC bought a new stake in shares of ARK Genomic Revolution ETF during the 3rd quarter valued at about $1,043,000. Finally, DLD Asset Management LP acquired a new position in ARK Genomic Revolution ETF during the 3rd quarter valued at approximately $1,509,000.

About ARK Genomic Revolution ETF

The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.